MRC License definition

MRC License means that certain License Agreement made October 1, 1993, between GenPharm International, Inc. (“GenPharm”, as of the Effective Date, a wholly owned subsidiary of Medarex, Inc.) and MRC, the Agricultural and Food Research Council Institute of Animal Physiology and Genetics Research of Babraham Hall (“AFRC”, as of the Effective Date, succeeded in title by the Babraham Institute) and [**], as amended by the Amendment Agreement made August 12, 1994 between GenPharm and MRC (on behalf of itself, AFRC and [**]) and further amended by the Letter Amendment dated April 19, 2002 between Medarex, Inc. (on behalf of itself and GenPharm) and MRC (on behalf of itself, the Babraham Institute and [**]), and the sublicense granted to Genmab thereunder pursuant to the Medarex License, as amended from time to time.
View Source
MRC License means the Agreement dated July 12, 1999 between the Medical Research Council and Seller, as successor in interest to LKS.
View Source
MRC License means that certain License Agreement entered by ------------ Medical Research Council, Institute of Animal Physiology and Genetics Research of Babraham Hall and ▇▇▇▇▇▇▇▇ BruggNmann and GenPharm International, Inc., effective October 1, 1993, as amended August 12, 1994, a copy of which is attached hereto as Exhibit A, as may be amended from time to time. ___________________ ***** REPRESENTS CONFIDENTIAL PORTION WHICH HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
View Source

Examples of MRC License in a sentence

  • Medarex shall be responsible for the --------------------- payment to the Medical Research Council ("MRC") of any royalties due the MRC pursuant to the MRC Agreement; provided, in the event that EOS obtains a direct license from the Medical Research Council with respect to the intellectual property subject to the MRC License, all royalties paid to the MRC under such a license with respect to Products shall be creditable against royalties due Medarex under Section 5.5.1, on a Product-by-Product basis.

  • TenX and its permitted sublicensees shall maintain accurate books and records sufficient to enable the verification of the calculation of royalties payable hereunder, and of royalties payable by under the Medarex License (including the MRC License) and under the Lonza Commercial License with respect to the sale by TenX and it sublicensees of Product, and of Additional Third Party Royalties.

  • Such reports will be clearly presented and shall be in any format and scope required under the MRC License or the Medarex License, as applicable, for the reporting of such royalties.

  • Royalty payments corresponding to [**] percent ([**]%) of MRC Net Sales of Product if such Product falls within the scope of “Product” for which royalties are payable pursuant to the MRC License.

  • The below table lists the various action items: [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] Below is a summary of the third-party payments payable under the Medarex License, the Lonza Commercial License, and the MRC License.

  • MRC License" shall mean the Agreement dated July 12, 1999 between the Medical Research Council and Seller, as successor in interest to LKS.

  • Unless expressly set forth herein, TenX shall pay to Genmab any and all applicable royalties, milestone fees and other license fees that are to be paid pursuant to the MRC License, the Medarex License and the Lonza Commercial License, including those described on Schedule D hereto, for the applicable term set forth in the respective agreement for the payment of such royalties and fees on the dates required pursuant to Section 6.10(b) or Section 6.10(c).

  • Under the terms of the MRC License (as --------------------- defined in Exhibit B) and the Dyax License (as defined in Exhibit B), CAT represents that GI, as consideration for GI's rights under such licenses, is obligated to pay CAT (for the benefit of Dyax and MRC) certain royalties on Net Sales of Licensed Products and Research Products ("GI/MRC/Dyax Sublicenses Royalties" at the royalty rates set forth in Exhibit B).

  • Subject to (a) CAT obligations as set forth in subparagraphs (i), (ii), and (iii) of this Section 14.2(b) and (b) GI's rights to the MRC License and Dyax License granted under this Agreement, CAT may, in its sole discretion, modify or amend such MRC and/or Dyax License(s), provided no such modification or amendment shall adversely affect GI's rights hereunder.